AstraZeneca’s Imfinzi Scores Neoadjuvant/Adjuvant NSCLC Two-fer At AACR

 
• By Alaric DeArment

The PD-L1 inhibitor showed efficacy in the neoadjuvant/adjuvant setting, where Merck is developing Keytruda as well. BMS’s Opdivo was the first to win approval in neoadjuvant NSCLC.

Lung Cancer
AstraZeneca announced data for Imfinzi in neoadjuvant/adjuvant non-small cell lung cancer at AACR • Source: Shutterstock

More from Clinical Trials

More from R&D